Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02656069
Previous Study | Return to List | Next Study

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02656069
Recruitment Status : Completed
First Posted : January 14, 2016
Results First Posted : September 28, 2018
Last Update Posted : October 30, 2018
Sponsor:
Information provided by (Responsible Party):
Xeris Pharmaceuticals

Brief Summary:
This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for hypoglycemia rescue of adult patients with type 1 diabetes.

Condition or disease Intervention/treatment Phase
Hypoglycemia Diabetes Mellitus, Type 1 Drug: G-Pen (glucagon injection) Drug: Lilly Glucagon (glucagon injection [rDNA origin]) Phase 3

Detailed Description:

This is a blinded, randomized, Phase 3 comparative efficacy and safety study in adults with type 1 diabetes. Patients will complete screening procedures up to 60 days before randomization to determine eligibility before enrollment to the treatment phase.

The procedure for evaluating the efficacy of the G-Pen (glucagon injection) consists of inducing hypoglycemia by intravenous administration of regular insulin diluted in normal saline. Each participant will undergo two episodes of insulin-induced hypoglycemia, and in random order will receive 1 mg G-Pen (glucagon injection) during one episode and 1 mg Lilly Glucagon during the other episode. There will be wash out period of 7-28 days between treatment visits.

Blood glucose levels will be monitored post-dosing, with a return of plasma glucose to a concentration > 70 mg/dL within 30 minutes signifying successful hypoglycemia rescue. As a confirmation of efficacy, subjects will complete a questionnaire concerning changes in symptoms of hypoglycemia following treatment with glucagon.

Subjects will return for a follow-up safety visit 3-14 days following administration of the final dose of glucagon.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
Actual Study Start Date : March 15, 2017
Actual Primary Completion Date : August 14, 2017
Actual Study Completion Date : September 25, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypoglycemia
Drug Information available for: Glucagon

Arm Intervention/treatment
G-Pen first, then Lilly Glucagon
A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
Drug: G-Pen (glucagon injection)
1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Other Name: glucagon

Drug: Lilly Glucagon (glucagon injection [rDNA origin])
1 mg of Lilly glucagon reconstituted from lyophilized powder
Other Name: glucagon

Lilly Glucagon first, then G-Pen
A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
Drug: G-Pen (glucagon injection)
1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Other Name: glucagon

Drug: Lilly Glucagon (glucagon injection [rDNA origin])
1 mg of Lilly glucagon reconstituted from lyophilized powder
Other Name: glucagon




Primary Outcome Measures :
  1. Hypoglycemia Rescue: Intent-to-Treat Population [ Time Frame: At 30 minutes following administration of study drug ]
    Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon

  2. Hypoglycemia Rescue: Per Protocol Population [ Time Frame: At 30 minutes following administration of study drug ]
    Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon

  3. Hypoglycemia Rescue: Alternate Glucose Response Definition [ Time Frame: At 30 minutes following administration of study drug ]
    Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or an increase in from baseline in plasma glucose concentration of at least 20 mg/dL within 30 minutes after administration of glucagon


Secondary Outcome Measures :
  1. Plasma Glucose Area Under the Curve (AUC) [ Time Frame: At -5, 0, 10, 20, 30, 45, 60, and 90 minutes following administration of glucagon ]
    Pharmacodynamic endpoint of plasma glucose AUC from baseline to 90 minutes following administration of glucagon

  2. Plasma Glucose Maximum Concentration (Cmax) [ Time Frame: At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon ]
    Pharmacodynamic endpoint of plasma glucose Cmax from baseline to 4 hours following administration of glucagon

  3. Plasma Glucose Time to Maximum Concentration (Tmax) [ Time Frame: At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon ]
    Pharmacodynamic endpoint of plasma glucose Tmax from baseline to 4 hours following administration of glucagon

  4. Plasma Glucose Time to Concentration > 70 mg/dL [ Time Frame: At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon ]
    Pharmacodynamic endpoint of time to achieve a plasma glucose concentration > 70 mg/dL following administration of glucagon

  5. Time to Resolution of Hypoglycemia Symptoms [ Time Frame: At 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 and 90 minutes following administration of glucagon ]
    Time to resolution of mean autonomic, mean neuroglycopenic and mean total hypoglycemia symptom scores from baseline through 90 minutes following administration of glucagon.

  6. Global Assessment of Hypoglycemia [ Time Frame: At 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 and 90 minutes following administration of glucagon ]
    Time to resolution of the overall sensation of hypoglycemia following administration of glucagon



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosed with type 1 diabetes mellitus for at least 24 months
  • usage of daily insulin treatment
  • random serum C-peptide concentration < 0.5 ng/mL

Exclusion Criteria:

  • pregnant or nursing
  • HbA1c >9.0%
  • renal insufficiency
  • hepatic synthetic insufficiency
  • aspartate or alanine aminotransferase > 3 times the upper limit of normal
  • hematocrit less than or equal to 30%
  • use of > 2.0 U/kg total insulin dose per day
  • inadequate bilateral venous access in both arms
  • congestive heart failure, New York Heart Association class II, III or IV
  • active malignancy within 5 years, except basal cell or squamous cell skin cancers
  • history of breast cancer or malignant melanoma
  • major surgical operation within 30 days
  • current seizure disorder.
  • current bleeding disorder, treatment with warfarin, or platelet count below 50,000
  • history of pheochromocytoma or disorder with increased risk of pheochromocytoma
  • history of insulinoma
  • history of glycogen storage disease.
  • positive for HIV, hepatitis C virus or active hepatitis B virus infection
  • whole blood donation of 1 pint (500 mL) within 8 weeks
  • active substance or alcohol abuse
  • administration of glucagon within 28 days
  • participation in other studies involving an investigational drug or device within 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02656069


Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, California
ProSciento, Inc.
Chula Vista, California, United States, 91911
AMCR Institute
Escondido, California, United States, 92025
Diablo Clinical Research
Walnut Creek, California, United States, 94598
United States, Texas
Clinical Trials of Texas, Inc.
San Antonio, Texas, United States, 78229
United States, Washington
Rainier Research
Renton, Washington, United States, 98057
Canada, Ontario
LMC Diabetes & Endocrinology
Toronto, Ontario, Canada, M4G 3E8
Sponsors and Collaborators
Xeris Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Xeris Pharmaceuticals:

Layout table for additonal information
Responsible Party: Xeris Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02656069     History of Changes
Other Study ID Numbers: XSGP-301
First Posted: January 14, 2016    Key Record Dates
Results First Posted: September 28, 2018
Last Update Posted: October 30, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Hypoglycemia
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Glucagon
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins